These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29239950)

  • 1. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
    Romano CA; Nair S; Delphin ES
    Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
    Bramstedt KA
    Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
    Garmendia CA; Bhansali N; Madhivanan P
    Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
    Shetty YC; Saiyed AA
    J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018.
    Rogers CA; Ahearn JD; Bartlett MG
    Ther Innov Regul Sci; 2020 Sep; 54(5):1123-1133. PubMed ID: 32096103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
    Bablani S; Janodia MD
    Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA; Kassimatis K
    Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".
    O'Reilly EK; Blair Holbein ME; Berglund JP; Parrish AB; Roth MT; Burnett BK
    Clin Invest Med; 2013 Dec; 36(6):E290-6. PubMed ID: 24309225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA; Epnere K; Bhansali N
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
    Bai HK; Ahearn JD; Bartlett MG
    Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T; Hackford C; Abraham L
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration.
    Gogtay NJ; Doshi BM; Kannan S; Thatte U
    Indian J Med Ethics; 2011; 8(4):211-4. PubMed ID: 22106658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
    Jung M; Swann RM; Anantha MS; Jamali F
    Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
    Seife C
    JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
    Bablani S; Janodia MD
    Ther Innov Regul Sci; 2019 Nov; ():2168479019879380. PubMed ID: 31690096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
    Rathore AS; Li Y; Chhabra H; Lohiya A
    J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
    Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
    [No Abstract]   [Full Text] [Related]  

  • 18. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
    Wang L; Zheng H; Ren X; Sun H
    Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF; Charrow RP
    JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA; Neumann PJ
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.